Source 1primary paper2025MED
Toolkit/sherpabody-guided CAR
sherpabody-guided CAR
Also known as: SbCAR, sherpabody-guided CARs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
incorporated into second-generation chimeric antigen receptor (CAR) constructs that were termed sherpabody-guided CARs (SbCAR)
Usefulness & Problems
Why this is useful
SbCARs are second-generation CAR constructs that use sherpabodies as the antigen-recognition domain. The abstract reports in vitro tumor-targeting activity, multispecific OR logic, and compatibility with synthetic Notch IF-THEN circuits.; targeted T-cell immunotherapy; solid-tumor CAR design; multispecific CAR logic engineering
Source:
SbCARs are second-generation CAR constructs that use sherpabodies as the antigen-recognition domain. The abstract reports in vitro tumor-targeting activity, multispecific OR logic, and compatibility with synthetic Notch IF-THEN circuits.
Source:
targeted T-cell immunotherapy
Source:
solid-tumor CAR design
Source:
multispecific CAR logic engineering
Problem solved
It provides a modular CAR architecture intended to improve specificity and persistence challenges in solid-tumor T-cell therapy.; embedding sherpabody binders into CAR constructs for tumor targeting; enabling modular multispecific and logic-gated CAR architectures
Source:
It provides a modular CAR architecture intended to improve specificity and persistence challenges in solid-tumor T-cell therapy.
Source:
embedding sherpabody binders into CAR constructs for tumor targeting
Source:
enabling modular multispecific and logic-gated CAR architectures
Problem links
embedding sherpabody binders into CAR constructs for tumor targeting
LiteratureIt provides a modular CAR architecture intended to improve specificity and persistence challenges in solid-tumor T-cell therapy.
Source:
It provides a modular CAR architecture intended to improve specificity and persistence challenges in solid-tumor T-cell therapy.
enabling modular multispecific and logic-gated CAR architectures
LiteratureIt provides a modular CAR architecture intended to improve specificity and persistence challenges in solid-tumor T-cell therapy.
Source:
It provides a modular CAR architecture intended to improve specificity and persistence challenges in solid-tumor T-cell therapy.
Published Workflows
Objective: Develop a modular SH3-derived targeting platform for CAR T-cell immunotherapy against solid tumors by selecting sherpabody binders to tumor-associated antigens and deploying them in CAR architectures with multispecific, logic-gated, and inducible formats.
Why it works: The abstract links phage-display selection of precise sherpabody binders with their modular incorporation into CAR constructs, then shows that the scaffold's small size and versatility support multispecific and logic-gated receptor designs that can be validated in vitro and in vivo.
SH3-derived antibody-mimetic antigen recognitionOR-logic multispecific activationIF-THEN logic with synthetic Notchinducible CAR controlphage display library selectionCAR construct engineeringin vitro functional testingxenograft mouse validation
Stages
- 1.Phage display identification of sherpabodies(broad_screen)
This stage generates antigen-binding sherpabodies that can serve as targeting modules for downstream CAR engineering.
Selection: Identification of sherpabodies against a panel of popular tumor-associated antigens.
- 2.Incorporation into second-generation CAR constructs(library_build)
This stage converts selected binders into functional T-cell receptor constructs for downstream testing.
Selection: Selected sherpabodies were incorporated into second-generation CAR constructs termed SbCAR.
- 3.In vitro functional characterization(functional_characterization)
This stage tests whether engineered SbCARs function specifically and kill target cells before in vivo evaluation.
Selection: Potent in vitro specificity and cytotoxicity against solid cancer TAAs without cross-reactivity to closely related proteins.
- 4.Logic and multispecific architecture characterization(secondary_characterization)
This stage extends baseline CAR function into more advanced circuit behaviors enabled by sherpabody modularity and small size.
Selection: Assessment of trispecific OR-logic activation and IF-THEN logic circuits in combination with synthetic Notch.
- 5.Xenograft mouse validation(in_vivo_validation)
This stage tests whether SbCAR T cells retain antitumor function in vivo after in vitro characterization.
Selection: Dose-dependent antitumor response in xenograft mouse models.
Steps
- 1.Identify sherpabodies against tumor-associated antigens by phage displayengineered binder being selected
Recover sherpabody binders against a panel of tumor-associated antigens.
Binder identification is required before the binders can be incorporated into CAR constructs.
- 2.Incorporate selected sherpabodies into second-generation CAR constructs to create SbCARsbinder converted into CAR targeting module
Build sherpabody-guided CAR constructs for T-cell testing.
The selected binders must be embedded in a CAR architecture before functional T-cell assays can be performed.
- 3.Test SbCARs for in vitro specificity and cytotoxicity and assess cross-reactivityCAR construct being functionally screened
Determine whether SbCARs specifically kill target cells while avoiding recognition of closely related proteins.
In vitro testing provides functional evidence before more complex logic designs or in vivo validation.
- 4.Build and test multispecific and logic-gated SbCAR variantsadvanced SbCAR variants being characterized
Evaluate whether sherpabody modularity supports trispecific OR logic, synthetic Notch IF-THEN logic, and inducible control formats.
Advanced circuit formats are enabled after establishing that the base sherpabody-guided CAR architecture functions.
- 5.Evaluate SbCAR T cells in xenograft mouse models for antitumor responsetherapeutic CAR T-cell product under in vivo validation
Test whether the engineered SbCAR platform produces antitumor activity in vivo.
Mouse validation follows in vitro functional evidence to assess therapeutic potential in a higher-fidelity setting.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
antigen recognition by sh3-derived antibody-mimetic binding domainscar-mediated t-cell activationor-logic multispecific activationsynthetic notch-mediated if-then logicTechniques
Selection / EnrichmentTarget processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedoperating role: actuator
The system requires selected sherpabody binders, CAR construct assembly, and engineered T cells. Some variants also require synthetic Notch or inducible-control components.; requires sherpabody binders selected against target antigens; requires incorporation into second-generation CAR constructs; requires engineered T cells for functional deployment
The abstract does not establish performance across all solid tumors or disclose the exact inducible mechanism and full construct details.; exact antigen panel and construct composition are not recoverable from the abstract alone
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Observations
successMammalian Cell Lineapplication demo
in vitro specificity and cytotoxicity assay
Inferred from claim c3 during normalization. SbCARs showed potent in vitro specificity and cytotoxicity against solid cancer tumor-associated antigens without cross-reactivity to closely related proteins. Derived from claim c3.
Source:
successMouseapplication demoxenograft mouse model
Inferred from claim c6 during normalization. SbCAR T cells elicited a dose-dependent antitumor response in xenograft mouse models. Derived from claim c6.
Source:
Supporting Sources
Ranked Claims
An inducible SbCAR system showed enhanced persistence and antitumor activity compared with constitutive CARs.
Sherpabodies selected by phage display were incorporated into second-generation CAR constructs termed SbCAR.
SbCAR T cells elicited a dose-dependent antitumor response in xenograft mouse models.
SbCAR-based circuits were combined with synthetic Notch to implement IF-THEN logic.
Trispecific SbCARs with OR logic robustly activated in response to cells expressing any or combinations of three cognate tumor-associated antigen targets.
SbCARs showed potent in vitro specificity and cytotoxicity against solid cancer tumor-associated antigens without cross-reactivity to closely related proteins.
Sherpabodies are SH3-derived antibody-mimetic proteins capable of precise tumor-associated antigen recognition.
Approval Evidence
1 source4 linked approval claimsfirst-pass slug sherpabody-guided-car
incorporated into second-generation chimeric antigen receptor (CAR) constructs that were termed sherpabody-guided CARs (SbCAR)
Source:
engineering resultsupports
Sherpabodies selected by phage display were incorporated into second-generation CAR constructs termed SbCAR.
Source:
in vivo efficacysupports
SbCAR T cells elicited a dose-dependent antitumor response in xenograft mouse models.
Source:
logic functionsupports
SbCAR-based circuits were combined with synthetic Notch to implement IF-THEN logic.
Source:
performancesupports
SbCARs showed potent in vitro specificity and cytotoxicity against solid cancer tumor-associated antigens without cross-reactivity to closely related proteins.
Source:
Comparisons
Source-stated alternatives
The abstract compares inducible SbCARs with constitutive CARs, and the upstream summary points to alternative non-scFv CAR targeting scaffolds such as Adnectin and DARPin.
Source:
The abstract compares inducible SbCARs with constitutive CARs, and the upstream summary points to alternative non-scFv CAR targeting scaffolds such as Adnectin and DARPin.
Source-backed strengths
potent in vitro specificity; cytotoxicity against solid cancer TAAs; no cross-reactivity to closely related proteins reported in the abstract; supports trispecific OR logic; compatible with synthetic Notch IF-THEN circuits
Source:
potent in vitro specificity
Source:
cytotoxicity against solid cancer TAAs
Source:
no cross-reactivity to closely related proteins reported in the abstract
Source:
supports trispecific OR logic
Source:
compatible with synthetic Notch IF-THEN circuits
Compared with coherent anti-Stokes Raman scattering
The abstract compares inducible SbCARs with constitutive CARs, and the upstream summary points to alternative non-scFv CAR targeting scaffolds such as Adnectin and DARPin.
Shared frame: source-stated alternative in extracted literature
Strengths here: potent in vitro specificity; cytotoxicity against solid cancer TAAs; no cross-reactivity to closely related proteins reported in the abstract.
Relative tradeoffs: exact antigen panel and construct composition are not recoverable from the abstract alone.
Source:
The abstract compares inducible SbCARs with constitutive CARs, and the upstream summary points to alternative non-scFv CAR targeting scaffolds such as Adnectin and DARPin.
Ranked Citations
- 1.